The Swaasa® AI platform represents a significant advancement in the field of respiratory health, particularly in India, where respiratory conditions such as Asthma, COPD, and pollution-related ailments impose a substantial health burden. Traditional diagnostic methods like spirometry and X-rays, although effective, are often inaccessible in remote and resource-limited areas and can be costly and time-consuming. Swaasa®, as a Software as a Medical Device (SaMD), leverages artificial intelligence to analyze cough sounds via an app, providing a rapid, contactless, and user-friendly method to screen for a variety of respiratory diseases, including COVID-19, TB, and Pneumonia. This innovation is particularly crucial in a country like India, where healthcare accessibility varies widely across its vast geography and diverse population.
To validate the commercial viability and acceptance of Swaasa® in the Indian healthcare landscape, a comprehensive study was conducted across eight states, partnering with Athena Infonomics. This commercial validation study involved interviews with a broad range of stakeholders, including Key Opinion Leaders (KOLs) such as doctors, healthcare technicians who operate the software, and the beneficiaries—patients using the service. The objective was to gather multifaceted insights into the functionality, ease of use, and clinical acceptance of Swaasa®, and to understand its potential role in the healthcare ecosystem. This study is pivotal in assessing the feasibility of implementing Swaasa® widely and in identifying the necessary enhancements to integrate it effectively within existing healthcare infrastructures.
To know more about the project, reach out to Trapti Malviya.
